Injectable GLP-1 receptor agonists, including semaglutide and tirzepatide, have redefined expectations for medical obesity therapy, achieving 15–20% weight reductions in clinical trials. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.